( 您好!臺灣時間:2021/07/26 07:32
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::


研究生(外文):Mei-Chun Yeh
論文名稱(外文):To synthetize dual function Pt-Fe-HAP magnetic particles for cancer hyperthermia
外文關鍵詞:HAPCisplatinhyperthermiachemotherapymagnetic particleco-pricipitationhysteresis loss
  • 被引用被引用:1
  • 點閱點閱:165
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
本研究利用共沉法製備氫氧基磷灰石,於過程中添加FeCl2.4H2O和K2PtCl4以改變氫氧基磷灰石的原子組成,反應過程中溫度維持在80 °C、pH=9~9.5。接著,利用傅立葉轉換紅外線光譜儀(Fourier transform infrared rays spectrometer,FTIR)、X-ray繞射儀(X-ray diffraction,XRD)分析材料的結構與特性,以掃描式電子顯微鏡(scanning electron microscopy,SEM)、能量散射光譜儀(Energy dispersive spectrometer)、感應耦合電漿發射光譜儀(Inductively coupled plasma-optical emission spectrometer,ICP-OES)探究材料表面形貌和化學性質;最後,再以震動樣品磁度儀(Vibrating sample magnetometer,VSM)分析磁特性。

Until 2011, cancer already is the top among the ten leading causes death over 28 years in Taiwan. The mortality from cancer is increasing every year. At Biomedicine field that focus on cancer therapies. Reducing side effects, decreasing pain and using effective therapies are the way that we hope for. “Thermotherapy” is the most popular one on cancer therapy. Synthesized with Fe2+ and Pt2+ and used Ca10(PO4)6(OH)2 to replace the Ca2+. By this way to let it got magnetic and have the same effect of Cisplatin. And then we got a Ca10(PO4)6(OH)2 that have composited effective.
The preparation for Ca10(PO4)6(OH)2 used Co-precipitation. During operated Co-precipitation that we add FeCl2.4H2O and K2PtCl4 to change compose of Ca10(PO4)6(OH)2 . Keeping temperature at 80 °C, and pH=9~9.5. And then used Fourier transform infrared rays spectrometer(FTIR) and X-ray diffraction(XRD) those two machine analyzed its’ composite and characteristic. Scanning electron microscopy (SEM), Energy dispersive spectrometer, and Inductively coupled plasma-optical emission spectrometer (ICP-OES) can helps us analyzed its’ surface and chemical property. Finally used Vibrating sample magnetometer (VSM) analyzed its’ magnetic characteristic.
Researching result show that it can prepare Ca10(PO4)6(OH)2 by using Co-precipitation. And the content of platinum is 0.034, and iron is 0.133. From the cart of Hystersis curve, it can prove the Ca10(PO4)6(OH)2 has magnetic. Commercial high frequency machine offered alternating current to find our magnetic. And then we can know the thermal energy from magnetic hysteresis. During 10 minutes can get the perfect temperature is 43~46°C.

摘要 I
致謝 IV
目錄 V
圖目錄 IXI
第一章 緒論 1
1.1 前言 1
1.2 認識癌症 3
1.3 癌症治療方法 4
1.3.1 外科手術 5
1.3.2 放射線療法 6
1.3.3 化學藥物療法 7
1.3.4 免疫療法 8
1.3.5 溫熱療法 9
1.4 癌症之熱治療 10
1.4.1 熱療之機制 10
1.4.2 熱療之方法 12
1.5 磁性顆粒於腫瘤熱治療之應用 14
1.6 研究目的 17
第二章 理論基礎 18
2.1 磁性概述 18
2.1.1 磁性來源[31] 18
2.1.2 磁性的分類[32-34] 19
2.1.3 磁性材料的放熱機制 22
2.2 氫氧基磷灰石 24
2.2.1 氫氧基磷灰石簡介 24
2.2.2 氫氧基磷灰石之結構 26
2.2.3 氫氧基磷灰石之合成方法 27
2.2.4 元素添加對氫氧基磷灰石之影響 29
2.3 化療藥物Cisplatin 30
2.3.1 Cisplatin之簡介 31
2.3.2 Cisplatin之作用機制 32
第三章 實驗材料與方法 34
3.1 實驗藥品 34
3.2 實驗儀器 35
3.3 材料製備 37
3.4 材料分析 39
3.4.1 X-ray繞射儀(XRD) 39
3.4.2 傅立葉轉換紅外線光譜儀(FT-IR Spectrometer) 39
3.4.3 場發射掃描式電子顯微鏡及能量散佈光譜儀(SEM&EDS) 40
3.4.4 感應耦合電漿/原子發射光譜儀(ICP-AES) 40
3.5 磁滯曲線與磁滯損失之量測 41
3.5.1 振動樣品磁力計(VSM) 41
3.5.2 超高週波加熱器 41
3.6 生物相容性測試 42
3.6.1 LDH細胞毒性測試 42
3.6.2 WST-1細胞增生測試 44
3.7 生物體外測試(In-Vitro) 46
3.7.1 材料對細胞增生之影響 46
3.7.2 材料之磁性加熱測試 47
第四章 結果與討論 48
4.1 X-Ray特性分析 48
4.2 FTIR圖譜分析 50
4.3 顯微結構觀察與元素成份分析 53
4.4 ICP-AES元素成分分析 55
4.5 磁滯曲線之VSM分析 56
4.6 材料之磁滯損失升溫效果 59
4.6.1 超高週波加熱器 59
4.6.2 熱量吸收率(Spesific power absorption rate, SAR) 61
4.7 LDH細胞毒性測試 62
4.8 WST-1細胞增生測試 63
4.9 生物體外測試(In-Vitro) 64
4.9.1 Pt2+對細胞增生活性之影響 65
4.9.2 磁性加熱之測試結果 66
第五章 結論 70
參考文獻 71

1.Organization, W. H. (2005).
2.Department of Health, Executive Yuan, R.O.C. 2011 (TAIWAN).
3.R.A. Weinberg, The biology of cancer, New York: Garland Science, (2006), ISBN 0-8153-4076-1.
4.B. Alberts, A. Johnson, J. Lewis, M. Raff, K. Roberts, and P. Walter, Molecular biology of the cell, New York: Garland Science, (2002), ISBN 0-8153-3218-1.
5.D.W. Kufe, R.E. Pollock, R.R. Weichselbaum, R.C. Bast Jr., T.S. Gansler, J.F. Holland, and E. Frei., Cancer Medicine 6, Hamilton (ON): BC Decker, (2003), ISBN 1-55009-213-8.
6.C.M. Haskell and J.S. Berek, Cancer Treatment, Philadelphia: WB Saunders, (1995), ISBN 0721649076.
9.李門輝,癌的基礎科學,台北:合計圖書出版社,(1987),第 213-241頁。
11.C.M. Haskell, “Immunologic aspects of cancer chemotherapy”, Annual Review of Pharmacology and Toxicology, Vol. 17, (1977), pp. 179-195.
12.E.M. Hersh, J.U. Gutterman, and G.M. Mavligit, “Immunotherapy of human cancer”, Advances in Internal Medicine, Vol. 22, (1977), pp. 145-185.
13.G. Mathe, Cancer Active Immunotherapy, Berlin and New York: Springer-Verlag, Vol. 55, (1976), pp. 1-402.
15.S. Licht, Therapeutic heat and cold, Baltimore: Waverly Press, (1965), pp. 196.
16.J. Overgaard, History and heritage: an introduction, London: Taylor and Francis, Vol. 2, (1985), pp. 3-8.
17.F. Westermark, “Uber die behandlung des ulceration cervixcarcinoma mittels konstanter warme”, Zentralbl Gynaekol, Vol. 22, (1898), pp. 1335.
18.G. Crile, “Selective destruction of cancers after exposure to heat”, Annals of Surgery, Vol. 156, (1962), pp. 404-407, pp. 414-416.
19.C.W. Song, “Effect of local hyperthermia on blood flow and microenvironment”, Cancer Research (SUPPL.), Vol. 44, (1984), pp. 4721s-4730s.
21.A. Chicheł, J. Skowronek, M. Kubaszewska, M. Kanikowski, “Hyperthermia-description of a method and a review of clinical applications”, Reports of Practical Oncology & Radiotherapy, Vol. 12, Issue 5, (2007), pp. 267-275.
22.C.J. Diederich, K. Hynynen, “Ultrasound technology for hyperthermia”, Ultrasound in Medicine and Biology, Vol. 25, Issue 6, (1999), pp. 871-887.
23.M.H. Seegenschmiedt, P. Fessenden, C.C. Vernon, Thermoradiotherapy and Thermochemotherapy, Berlin: Springer, Vol. 1: Biology, Physiology, Physics, (1995), pp. 253-278.
24.W.L. Lin, Y.Y. Chen, J.Y. Yen, “Technical consideration for advanced ultrasound hyperthermia system development”, Japan Journal of Hyperthermic Oncology, Vol. 14, (1998), pp. S59-S61.
25.I. Manak, A. Lisenkova, A. Nikolaeva, “Laser hyperthermia: Problems and solutions”, Proceedings of SPIE, Vol. 5566, (2004), pp. 178-184.
26.S. Mornet, S, Vasseur, F. Grasset, E. Duguet, “Magnetic nanoparticle design for medical diagnosis and therapy”, Journal of Materials Chemistry, Issue 14, (2004), pp. 2161-2175.
27.P. Moroz, S.K. Jones, B.N. Gray, “Magnetically mediated hyperthermia: current status and future directions”, International Journal of Hyperthermia, Vol. 18, No. 4, (2002), pp. 267-284.
28.C. Plank, "Nanomagnetosols: magnetism opens up new perspectives for targeted aerosol delivery to the lung", Trends in Biotechnology, Vol. 26, Issue 2, (2008), pp. 59-63.
29.X. Wang, L. Yang, Z. Chen, D.M. Shin, “Application of Nanotechnology in Cancer Therapy and Imaging”, CA: A Cancer Journal for Clinicians, Vol. 58, Issue 2, (2008), pp. 97-110.
30.G. Kong, G. Anyarambhatla, W.P. Petros, R.D. Braun, O.M. Colvin, D. Needham, M.W. Dewhirst, “Efficacy of Liposome and Hyperthermia in a Human Tumor Xenograft Model: Importance of Triggered Drug Release”, Cancer Research, Vol. 60, (2000), pp. 6950-6957.
32.張煦,李學養,磁性物理學,台北:聯經出版事業公司,(1982) ,第3-15頁。
36.W. Andra, H. Nowak, Magnetism in Medicine: A Handbook, Berlin: Wiley-VCH, (1998), pp. 455.
37.Q.A. Pankhurst, J. Connolly, S.K. Jones, J. Dobson, “Applications of magnetic nanoparticles in biomedicine”, Journal of Physics D: Applaied Physics, Vol. 36, (2003), pp. R167-R181.
38.F. H. Albee, H. F. Morrison, "Studies in bone growth-Triple calcium phosphate as a stimulus to osteogenesis", Annals of Surgery, Vol. 71, Issue 1, (1920), pp. 32-39.
39.W.F. Dejong, “La Substance Minerale Dans les Os”, Recueil des Travaux Chimiques des Pays-Bas, Vol. 45, Issue 6, (1926), pp. 445-448.
40.C.S. Chai, B. Ben-Nissan, “Bioactive nanocrystalline sol-gel hydroxyapatite coating”, Journal of Materials Science: Materials in Medicine, Vol. 10, (1999), pp. 465-469.
41.S.D. Bruck, Properties of biomaterials in the physiological environment, Boca Raton, Florida: CRC Press, (1980), pp. 1.
42.L.L. Hench, “Bioceramics: from concept to clinic”, Journal of the American Ceramic Society, Vol. 74, Issue 7, (1991), pp. 1487-1510.
44.M.S.-A. Johnsson, G.H. Nanocollas, “The Role of Brushite and Octacalcium Phosphate in Apatite Formation”, Critical Reviews in Oral Biology and Medicine, Vol. 3, Issue 1/2, (1992), pp. 61-82.
45.J.D. Bronzino, The Biomedical Engineering Handbook, Boca Raton, Florida: CRC Press, (1995), pp. 562.
46.L. Bernard, M. Freche, J.L. Lacout, B. Biscans, “Preparation of hydroxyapatite by neutralization at low temperature—influence of purity of the raw material”, Powder Technology, Vol. 103, (1999), pp. 19-25.
47.C. Liu, Y. Huang, W. Shen, J. Cui, “Kinetics of hydroxyapatite precipitation at pH 10 to 11”, Biomaterials, Vol. 22, (2001), pp. 301-306.
50.G. Willmann, “Medical grade hydroxyapatite: state of the art”, British Ceramic Transactions, Vol. 95, (1996), pp. 212-216.
51.B. Desoize, "Metals and metal compounds in cancer treatment", Anticancer Research, Vol. 24, (2004), pp. 1529-1544.
53.R.T. Skeel, S. Khleif, Handbook of Cancer Chemotherapy, Taiwan: Lippincott Williams & Wilkins, (1999).
54.K. Stehlikova, H. Kostrhunova, J. Kasparkova, V. Brabec, “DNA bending and unwinding due to the major 1,2-GG intrastrand cross-link formed by antitumor cis-diamminedichloroplatinum(II) are flanking-base independent”, Nucleic Acids Research, Vol. 30, No. 13, (2002), pp. 2894-2898.
55.D.B. Zamble, S.J. Lippard, “Cisplatin and DNA Repair in Cancer Chemotherapy”, Trends in Biochemical Sciences, Vol. 20, Issue 10, (1995), pp. 435-439.
56.E.R. Jamieson, S.J. Lippard, “Structure, Recognition, and Processing of Cisplatin−DNA Adducts”, Chemical Reviews, Vol. 99, No. 9, (1999), pp. 2467-2498.
57.M. Kartalou, J.M. Essigmann, “Mechanisms of Resistance to Cisplatin”, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, Vol. 478, Issue 1-2, (2001), pp. 23-43.
58.D. Wang, S.J. Lippard, “Cellular Processing of Platinum Anticancer Drugs”, Nature Reviews Drug Discovery 4, Vol. 4, (2005), pp. 307-320.
59.Bio Vision, LDH-Cytotoxicity Assay Kit, Montain View: Bio Vision Research Products, Catalog#K311-400.
60.Takara, Premix WST-1 Cell Proliferation Assay System, Takara, Catalog ﹟MK400.
61.C.C. Silva, D. Thomazini, A.G. Pinheiro, F. Lanciotti Jr., J.M. Sasaki, J.C. Goes, A.S.B. Sombra, “Optical Properties of Hydroxyapatite Obtained by Mechanical Alloying”, Journal of Physics and Chemistry of Solids, Vol. 63, Issue 9, (2002), pp. 1745-1757.
62.K. Kandori, N. Horigami, A. Yasukawa, T. Ishikawa, “Texture and Formation Mechanism of Fibrous Calcium Hydroxyapatite Particles Prepared by Decomposition of Calcium–EDTA Chelates”, Journal of the American Ceramic Society, Vol. 80, Issue 5, (1997), pp. 1157-1164.
63.L.L. Hench, J. Wilson, An Introduction to Bioceramics, Singapore: World Scientific, (1993).

註: 此連結為研究生畢業學校所提供,不一定有電子全文可供下載,若連結有誤,請點選上方之〝勘誤回報〞功能,我們會盡快修正,謝謝!
第一頁 上一頁 下一頁 最後一頁 top
1. 趙明玲、高淑芬(1997)。父親照顧家中重度慢性疾病兒的經驗感受。長庚護理,8(3),34-42。
2. 趙明玲、高淑芬(1997)。父親照顧家中重度慢性疾病兒的經驗感受。長庚護理,8(3),34-42。
3. 黃明月、林宜穎、葉書秀(2008)。外籍配偶子女教養方式及其轉化學習之方案發展研究。課程與教學季刊,11(4),75-108。
4. 黃明月、林宜穎、葉書秀(2008)。外籍配偶子女教養方式及其轉化學習之方案發展研究。課程與教學季刊,11(4),75-108。
5. 黃明月、林宜穎、葉書秀(2008)。外籍配偶子女教養方式及其轉化學習之方案發展研究。課程與教學季刊,11(4),75-108。
6. 黃明月、林宜穎、葉書秀(2008)。外籍配偶子女教養方式及其轉化學習之方案發展研究。課程與教學季刊,11(4),75-108。
7. 張淑娟(2002)。觀點轉化學習理論在成人教育中的省思。成人教育,68,35-43。
8. 張淑娟(2002)。觀點轉化學習理論在成人教育中的省思。成人教育,68,35-43。
9. 張淑娟(2002)。觀點轉化學習理論在成人教育中的省思。成人教育,68,35-43。
10. 張淑娟(2002)。觀點轉化學習理論在成人教育中的省思。成人教育,68,35-43。
11. 陳毓文、鄭玲惠(2000)。為什麼是我?胰島素依賴型糖尿病少年生活經驗之初探。中華心理衛生學刊,13(1),1-26。
12. 陳毓文、鄭玲惠(2000)。為什麼是我?胰島素依賴型糖尿病少年生活經驗之初探。中華心理衛生學刊,13(1),1-26。
13. 陳毓文、鄭玲惠(2000)。為什麼是我?胰島素依賴型糖尿病少年生活經驗之初探。中華心理衛生學刊,13(1),1-26。
14. 陳毓文、鄭玲惠(2000)。為什麼是我?胰島素依賴型糖尿病少年生活經驗之初探。中華心理衛生學刊,13(1),1-26。
15. 陳明蕾(1999)。一個新的學習典範:觀點轉化學習理論。成人教育學刊,3,1-32。